Letermovir in paediatric HSCT recipients

J Antimicrob Chemother. 2019 Sep 1;74(9):2820-2821. doi: 10.1093/jac/dkz218.

Authors

Volker Strenger¹, Daniela Sperl¹, Klaus Kubesch², Josef Donnerer³, Wolfgang Schwinger¹, Klara Zach¹, Herwig Lackner¹, Martin Benesch¹

Affiliations

¹ Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
² pharm-analyt Labor GmbH, Baden, Austria.
³ Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.

PMID: 31139834
DOI: 10.1093/jac/dkz218

No abstract available

Publication types

Letter

MeSH terms

Acetates / administration & dosage
Acetates / adverse effects
Acetates / therapeutic use*
Antiviral Agents / administration & dosage
Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use*
Child
Cytomegalovirus Infections / drug therapy
Cytomegalovirus Infections / etiology
Graft vs Host Disease / diagnosis
Graft vs Host Disease / etiology
Hematopoietic Stem Cell Transplantation* / adverse effects
Hematopoietic Stem Cell Transplantation* / methods
Humans
Liver Diseases / diagnosis
Liver Diseases / etiology
Quinazolines / administration & dosage
Quinazolines / adverse effects
Quinazolines / therapeutic use*
Transplant Recipients*

Substances

Acetates
Antiviral Agents
Quinazolines
letermovir